secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mural Oncology plc (—)
CIK:        0001971543
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001193125-23-277530
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 3.03, 5.03, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mural Oncology spins off from Alkermes with $275M funding; nemvaleukin trials readout in 1Q2025
--------------------------------------------------------------------------------

- Spin-off completed Nov 15, 2023; Mural shares trade on Nasdaq under 'MURA' starting Nov 16.
- $275M committed funding provides cash runway projected into 4Q 2025.
- Lead candidate nemvaleukin in two potentially registrational trials; top-line data expected 1Q 2025.
- Preclinical IL-18 and IL-12 programs; development candidate nominations planned in 2024.
- Executive team includes CEO Caroline Loew, CFO Adam Cutler, CMO Vicki Goodman; board chaired by Scott Jackson.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971543/000119312523277530/0001193125-23-277530-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971543/000119312523277530/d319165d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-277530

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer